A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

The study also noticed some other effects of statins. Some people taking these drugs gained weight or had an increase in body ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

He must be the catalyst and not an inhibitor. All his actions must be impelled, keeping in mind the dignity of the high constitutional office.” India needs fair, non-hyphenated and questioning ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% reduction in LDL cholesterol at 12 weeks in patients with hypercholesterolemia ...